🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

An Exploratory Study to Evaluate Immune Determinants of the Response to Adoptive Cell Therapy (ACT) in Solid and Hematologic Tumors

RecruitingNAAges 2 Years - anyAllGustave Roussy, Cancer Campus, Grand Paris
NCT05481502 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This is a study to explore the phenotypic and transcriptional changes of different cellular components in the tumor following the injection of somatic cell therapy drugs. The second objective is to explore phenotypic and transcriptional changes of different cellular components in blood and bone marrow following injection of somatic cell therapy drugs.Then correlate the phenotypic and transcriptional profile of different tumor, blood and bone marrow immune populations with clinical response and/or toxicity. And to finish this study is designed in order to identify a phenotypic, transcriptional and epigenetic profile of intra-tumoral adoptive cells and correlate this profile with clinical response and/or toxicity.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Patient affiliated to a social security regimen * Tumor lesion accessible to core biopsies * Patient who is fully informed, able to comply with the protocol and who signed the informed consent * Pediatric patients \> than 2 years old can be included * No restriction about the Eastern Cooperative Oncology Group (ECOG) status Exclusion Criteria: * Coagulation abnormality prohibiting a biopsy (but patients can still give their consent for blood and bone marrow samples). * Tumor lesion not accessible to core biopsies. * Pregnant or nursing women cannot participate in this study.
💊

What it tests

  • Tumor biopsy
  • Blood sample
  • Bone marrow sample
📍

Where

1 site
Gustave Roussy Cancer Campus Grand Paris
Villejuif, France
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy